Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | GRK5 | P34947 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442956 | 0.82 | NOTUM (1.00) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL23863307 | 0.82 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL5502 | 0.82 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL14069278 | 0.82 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL7898072 | 0.82 | PTGS2 (0.48) | NOTUMRAB9ANPC1MAPTTP53 | |
| SCHEMBL8418866 | 0.82 | MAPT (0.51) | NOTUMRAB9ANPC1MAPTTP53 | |
| SCHEMBL20536341 | 0.82 | NOTUM (0.47) | NOTUMRAB9ANPC1MAPTTP53 | |
| SCHEMBL2427499 | 0.82 | NOTUM (0.51) | NOTUMRAB9ANPC1MAPTTP53 | |
| SCHEMBL1544128 | 0.81 | NOTUM (1.00) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL2983289 | 0.81 | NOTUM (0.64) | NOTUMCHEK1AURKADAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| WO-2025085347-A1 | IL4I1 INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085148-A1 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | NOTUM 2246/4885CHEK1 1808/4885AURKA 1807/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | NOTUM 293/4885CHEK1 2922/4885AURKA 1185/4885 |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | NOTUM 2320/4885CHEK1 2481/4885AURKA 1612/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | NOTUM 4592/4885CHEK1 4272/4885AURKA 4542/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | NOTUM 293/4885CHEK1 2922/4885AURKA 1185/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | NOTUM 4801/4885CHEK1 1932/4885AURKA 3525/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | NOTUM 2621/4885CHEK1 3867/4885AURKA 3306/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | NOTUM 3291/4885CHEK1 1634/4885AURKA 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.